MX2020007152A - Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. - Google Patents

Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.

Info

Publication number
MX2020007152A
MX2020007152A MX2020007152A MX2020007152A MX2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A MX 2020007152 A MX2020007152 A MX 2020007152A
Authority
MX
Mexico
Prior art keywords
amine
substituted heterocyclic
methods
synthesis
salts
Prior art date
Application number
MX2020007152A
Other languages
English (en)
Inventor
Michael John Munchhof
John Emmerson Campbell
James Edward John Mills
Kenneth William Duncan
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of MX2020007152A publication Critical patent/MX2020007152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente divulgación se refiere a compuestos heterocíc1icos sustituidos con amina. La presente divulgación también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar un trastorno (por ejemplo, cáncer) mediante la administración de un compuesto heterocíc1ico sustituido con amina desvelado en este documento o una composición farmacéutica del mismo en sujetos con necesidad del mismo. La presente divulgación también se refiere al uso de tales compuestos en investigación u otros fines no terapéuticos.
MX2020007152A 2017-10-18 2018-10-18 Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. MX2020007152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18
PCT/US2018/056428 WO2019079540A1 (en) 2017-10-18 2018-10-18 AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF

Publications (1)

Publication Number Publication Date
MX2020007152A true MX2020007152A (es) 2020-12-10

Family

ID=66173899

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007152A MX2020007152A (es) 2017-10-18 2018-10-18 Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
MX2024012124A MX2024012124A (es) 2017-10-18 2020-07-13 Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024012124A MX2024012124A (es) 2017-10-18 2020-07-13 Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.

Country Status (16)

Country Link
US (2) US20200247790A1 (es)
EP (1) EP3697762A4 (es)
JP (2) JP2021500334A (es)
KR (1) KR20200101330A (es)
CN (1) CN111417628A (es)
AU (2) AU2018353122B2 (es)
BR (1) BR112020007632A2 (es)
CA (1) CA3079273A1 (es)
CL (1) CL2020001009A1 (es)
CO (1) CO2020005944A2 (es)
EA (1) EA202090959A1 (es)
IL (2) IL301746B2 (es)
MA (1) MA50418A (es)
MX (2) MX2020007152A (es)
SG (1) SG11202003225YA (es)
WO (1) WO2019079540A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式
WO2025240956A1 (en) * 2024-05-17 2025-11-20 Yale University G9a/ehmt2 inhibitor use for prader-willi syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004272288B2 (en) * 2003-09-18 2008-11-13 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) * 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
JP2017519017A (ja) * 2014-06-23 2017-07-13 ジェネンテック， インコーポレイテッド 癌の治療及び癌薬剤耐性の防止方法
IL307931A (en) * 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
MA47233A (fr) * 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
US20210213014A1 (en) * 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies

Also Published As

Publication number Publication date
US20220324851A1 (en) 2022-10-13
AU2018353122A1 (en) 2020-06-04
IL301746A (en) 2023-05-01
IL301746B2 (en) 2025-01-01
JP2021500334A (ja) 2021-01-07
CO2020005944A2 (es) 2020-07-31
MX2024012124A (es) 2025-02-10
IL273974B1 (en) 2023-04-01
CA3079273A1 (en) 2019-04-25
AU2018353122B2 (en) 2023-11-23
SG11202003225YA (en) 2020-05-28
KR20200101330A (ko) 2020-08-27
JP2023036991A (ja) 2023-03-14
CN111417628A (zh) 2020-07-14
BR112020007632A2 (pt) 2020-09-29
US20200247790A1 (en) 2020-08-06
EP3697762A1 (en) 2020-08-26
WO2019079540A1 (en) 2019-04-25
EA202090959A1 (ru) 2020-07-13
AU2024201165A1 (en) 2024-03-14
CL2020001009A1 (es) 2020-12-18
IL301746B1 (en) 2024-09-01
MA50418A (fr) 2021-04-07
EP3697762A4 (en) 2021-04-07
IL273974B2 (en) 2023-08-01
IL273974A (en) 2020-05-31

Similar Documents

Publication Publication Date Title
ZA201904234B (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
MX2022010947A (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2.
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
MX2024012124A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
NZ706739A (en) Substituted benzene compounds
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX344530B (es) Compuestos de benceno substituido.
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
EP4360712A3 (en) Aryl- or heteroaryl-substituted benzene compounds
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
PH12018500446A1 (en) Pyridinone dicarboxamide for use as bromodomain inhibitors
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
EA201991509A1 (ru) Аминозамещенные гетероциклические соединения в качестве ингибиторов ehmt2 и способы их применения
UA110969C2 (uk) Арил- або гетероарилзаміщені бензольні сполуки та фармацевтична композиція на їх основі
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors